Cargando…

Neurodegeneration in MS and NMO: The Eye and the Blood

Detalles Bibliográficos
Autores principales:	Petzold, Axel, Geurts, Jeroen J. G., Nakashima, Ichiro, Butzkueven, Helmut, Weissert, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3238404/ https://www.ncbi.nlm.nih.gov/pubmed/22203903 http://dx.doi.org/10.1155/2011/842797

Ejemplares similares

Secondary progression and innate immunity in NMO: A possible link to alemtuzumab therapy?
por: Fujihara, Kazuo, et al.
Publicado: (2014)

Finding NMO
por: Daneman, Richard
Publicado: (2016)

Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD
por: Zeka, Bleranda, et al.
Publicado: (2016)

Lack of KIR4.1 autoantibodies in Japanese patients with MS and NMO
por: Higuchi, Osamu, et al.
Publicado: (2016)

Vitamin D and Demyelinating Diseases: Neuromyelitis Optica (NMO) and Multiple Sclerosis (MS)
por: Rodney, Cady, et al.
Publicado: (2020)

Therapy of NMO spectrum disorders
por: Biswas, Atanu, et al.
Publicado: (2015)

Myelinodegeneration vs. Neurodegeneration in MS Progressive Forms
por: Nataf, Serge
Publicado: (2023)

Neuromyelitis optica (NMO) and autoimmune thyroiditis
por: Sudulagunta, Sreenivasa Rao, et al.
Publicado: (2015)

Autoimmune thyroiditis associated with neuromyelitis optica (NMO)
por: Sudulagunta, Sreenivasa Rao, et al.
Publicado: (2015)

Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Disease: CHANCE(NMO) Study
por: Hümmert, Martin W., et al.
Publicado: (2022)

Neurofilament Proteins as Body Fluid Biomarkers of Neurodegeneration in Multiple Sclerosis
por: Gresle, Melissa M., et al.
Publicado: (2011)

NMO-IgG: A Specific Biomarker for Neuromyelitis Optica
por: Weinshenker, Brian G., et al.
Publicado: (2006)

Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis
por: Borisow, Nadja, et al.
Publicado: (2018)

Where Do AQP4 Antibodies Fit in the Pathogenesis of NMO?
por: Kinoshita, Makoto, et al.
Publicado: (2012)

Wallenda-Nmo Axis Regulates Growth via Hippo Signaling
por: Wang, Xianping, et al.
Publicado: (2021)

Wernicke’s Encephalopathy Precipitated by Area Postrema Syndrome of NMO-SD
por: Anuradha, Mahto, et al.
Publicado: (2023)

Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO
por: Gelfand, Jeffrey M., et al.
Publicado: (2014)

Statins: a revised appraisal for potential additional future treatment indications
por: Weissert, Robert
Publicado: (2012)

Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS
por: Zeka, Bleranda, et al.
Publicado: (2015)

Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)
por: Vaknin-Dembinsky, Adi, et al.
Publicado: (2016)

3D-DIR for early differential diagnostic and prognostic evaluation of NMO
por: Wang, Yanbing, et al.
Publicado: (2016)

Identification of geraldol as an inhibitor of aquaporin-4 binding by NMO-IgG
por: Wang, Jie, et al.
Publicado: (2020)

COVID-19 infection in NMO/SD patients: a French survey
por: Zeidan, Sinéad, et al.
Publicado: (2020)

Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling
por: Yeo, Tianrong, et al.
Publicado: (2019)

An Atypical Presentation of Chronic Inflammatory Myelin Degeneration in Neuromyelitis Optica (NMO)
por: Allu, Sai Vishnu Vardhan, et al.
Publicado: (2023)

Blood biomarkers of neurodegeneration—progress on non-invasive diagnostics
Publicado: (2021)

An Optimized Immunohistochemistry Technique Improves NMO-IgG Detection: Study Comparison with Cell-Based Assays
por: Höftberger, Romana, et al.
Publicado: (2013)

Unmasking and provoking severe disease activity in a patient with NMO spectrum disorder
por: Kornberg, Michael D., et al.
Publicado: (2015)

Mitoxantrone in NMO Spectrum Disorder in a Large Multicenter Cohort in French Caribbean
por: Chaumont, Hugo, et al.
Publicado: (2023)

Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?
por: Maillart, Elisabeth, et al.
Publicado: (2020)

Passively transferred human NMO-IgG exacerbates demyelination in mouse experimental autoimmune encephalomyelitis
por: Saini, Harleen, et al.
Publicado: (2013)

Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): Development of a globally applicable quality improvement tool
por: Hobart, Jeremy, et al.
Publicado: (2022)

Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMO
por: Kitley, Joanna, et al.
Publicado: (2015)

Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study
por: Valentino, Paola, et al.
Publicado: (2016)

Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects
por: Brod, Staley A.
Publicado: (2020)

Zoom in on neurodegeneration
por: Bu, Guojun, et al.
Publicado: (2006)

Isoaspartate and neurodegeneration
por: Wang, Jijing, et al.
Publicado: (2022)

Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients
por: van Kempen, Zoé LE, et al.
Publicado: (2021)

Comparative Analysis for the Presence of IgG Anti-Aquaporin-1 in Patients with NMO-Spectrum Disorders
por: Sánchez Gomar, Ismael, et al.
Publicado: (2016)

Cancer and neurodegeneration meet
por: de Strooper, Bart
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_9rgbeo3cervr7e1lep73itgf3d